Aspirin and cancer risk: A quantitative review to 2011

Annals of Oncology

Volumn 23, Issue 6, 2012, Pages 1403-1415

  Bosetti, C ^a   Rosato, V ^a,b   Gallus, S ^a   Cuzick, J ^c   La Vecchia, C ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Aspirin; Epidemiology; Meta analysis; Neoplasm; Nonsteroidal anti inflammatory drugs; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID;

BLADDER CANCER; BREAST CANCER; CANCER RISK; CARDIA CARCINOMA; CASE CONTROL STUDY; COHORT ANALYSIS; COLORECTAL CANCER; DRUG EFFICACY; ENDOMETRIUM CANCER; ESOPHAGEAL ADENOCARCINOMA; HUMAN; KIDNEY CANCER; LUNG CANCER; META ANALYSIS; OBSERVATIONAL STUDY; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE STUDY; REVIEW; RISK REDUCTION; STOMACH ADENOCARCINOMA;

EID: 84861722871     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds113     Document Type: Review

References (111)

1. Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: an update to 2001. Eur J Cancer Prev 2002; 11: 535-542.
2. Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 2006; 17: 871-888.
3. Cuzick J, Otto F, Baron JA et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009; 10: 501-507.
4. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998; 90: 1529-1536.
5. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst 1998; 90: 1609-1620.
6. Fiorucci S, Antonelli E. Cyclo-oxygenase isoenzymes. Structural basis for selective inhibition of cyclo-oxygenases by anti-inflammatory agents. Dig Liver Dis 2001; 33 (Suppl 2): S2-S7.
7. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252-266.
8. Elwood PC, Gallagher AM, Duthie GG et al. Aspirin, salicylates, and cancer. Lancet 2009; 373: 1301-1309.
9. Langley RE, Burdett S, Tierney JF et al. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer 2011; 105: 1107-1113.
10. Abnet CC, Freedman ND, Kamangar F et al. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer 2009; 100: 551-557.
11. Yang P, Zhou Y, Chen B et al. Aspirin use and the risk of gastric cancer: a meta-analysis. Dig Dis Sci 2010; 55: 1533-1539.
12. Mangiapane S, Blettner M, Schlattmann P. Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. Pharmacoepidemiol Drug Saf 2008; 17: 115-124.
13. Takkouche B, Regueira-Mendez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 2008; 100: 1439-1447.
14. Zhao YS, Zhu S, Li XW et al. Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. Breast Cancer Res Treat 2009; 117: 141-150.
15. Luo T, Yan HM, He P et al. Aspirin use and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2012; 131: 581-587.
16. Larsson SC, Giovannucci E, Bergkvist L, Wolk A. Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 2561-2564.
17. Oh SW, Myung SK, Park JY et al. Aspirin use and risk for lung cancer: a metaanalysis. Ann Oncol 2011; 22: 2456-2465.
18. Mahmud SM, Franco EL, Aprikian AG. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer 2010; 127: 1680-1691.
19. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
20. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978; 31: 691-696.
21. Gridley G, McLaughlin JK, Ekbom A et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85: 307-311.
22. Kauppi M, Pukkala E, Isomaki H. Low incidence of colorectal cancer in patients with rheumatoid arthritis. Clin Exp Rheumatol 1996; 14: 551-553.
23. Friis S, Thomassen L, Sorensen HT et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Eur J Cancer Prev 2008; 17: 88-96.
24. Rothwell PM, Wilson M, Elwin CE et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376: 1741-1750.
25. Rothwell PM, Fowkes FG, Belch JF et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41.
26. Seshasai SR, Wijesuriya S, Sivakumaran R et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172: 209-216.
27. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
28. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987; 9: 1-30.
29. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
30. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
31. Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol 2000; 53: 207-216.
32. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer 1993; 72: 1171-1177.
33. Friedman GD, Coates AO, Potter JD, Slattery ML. Drugs and colon cancer. Pharmacoepidemiol Drug Saf 1998; 7: 99-106.
34. Sansbury LB, Millikan RC, Schroeder JC et al. Use of nonsteroidal antiinflammatory drugs and risk of colon cancer in a population-based, case-control study of African Americans and Whites. Am J Epidemiol 2005; 162: 548-558.
35. Harris RE, Beebe-Donk J, Alshafie GA. Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2008; 8: 237.
36. Kim S, Martin C, Galanko J et al. Use of nonsteroidal antiinflammatory drugs and distal large bowel cancer in whites and African Americans. Am J Epidemiol 2008; 168: 1292-1300.
37. Rennert G, Rennert HS, Pinchev M, Gruber SB. A case-control study of levothyroxine and the risk of colorectal cancer. J Natl Cancer Inst 2010; 102: 568-572.
38. Din FV, Theodoratou E, Farrington SM et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 2010; 59: 1670-1679.
39. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989; 299: 1247-1250.
40. Thun MJ, Namboodiri MM, Calle EE et al. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322-1327.
41. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994; 5: 138-146.
42. Garcia-Rodriguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 2001; 12: 88-93.
43. Ratnasinghe LD, Graubard BI, Kahle L et al. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 2004; 24: 3177-3184.
44. Chan AT, Giovannucci EL, Meyerhardt JA et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005; 294: 914-923.
45. Allison M, Garland C, Chlebowski R et al. The association between aspirin use and the incidence of colorectal cancer in women. Am J Epidemiol 2006; 164: 567-575.
46. Larsson SC, Giovannucci E, Wolk A. Long-term aspirin use and colorectal cancer risk: a cohort study in Sweden. Br J Cancer 2006; 95: 1277-1279.
47. Mahipal A, Anderson KE, Limburg PJ, Folsom AR. Nonsteroidal antiinflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev 2006; 15: 1785-1790.
48. Chan AT, Manson JE, Feskanich D et al. Long-term aspirin use and mortality in women. Arch Intern Med 2007; 167: 562-572.
49. Jacobs EJ, Thun MJ, Bain EB et al. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007; 99: 608-615.
50. Vinogradova Y, Hippisley-Cox J, Coupland C, Logan RF. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology 2007; 133: 393-402.
51. Siemes C, Visser LE, Coebergh JW et al. Protective effect of NSAIDs on cancer and influence of COX-2 C(-765G) genotype. Curr Cancer Drug Targets 2008; 8: 753-764.
52. Friis S, Poulsen AH, Sorensen HT et al. Aspirin and other non-steroidal antiinflammatory drugs and risk of colorectal cancer: a Danish cohort study. Cancer Causes Control 2009; 20: 731-740.
53. Slattery ML, Samowitz W, Hoffman M et al. Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. Cancer Epidemiol Biomarkers Prev 2004; 13: 538-545.
54. Chan AT, Giovannucci EL, Meyerhardt JA et al. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 2008; 134: 21-28.
55. Rosenberg L, Louik C, Shapiro S. Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer 1998; 82: 2326-2333.
56. Farrow DC, Vaughan TL, Hansten PD et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998; 7: 97-102.
57. Duan L, Wu AH, Sullivan-Halley J, Bernstein L. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomarkers Prev 2008; 17: 126-134.
58. Epplein M, Nomura AM, Wilkens LR et al. Nonsteroidal antiinflammatory drugs and risk of gastric adenocarcinoma: the multiethnic cohort study. Am J Epidemiol 2009; 170: 507-514.
59. Bertuccio P, Bravi F, Bosetti C et al. Aspirin and gastric cancer risk. Eur J Cancer Prev 2010; 19: 426-427.
60. Terry MB, Gammon MD, Zhang FF et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004; 291: 2433-2440.
61. Swede H, Mirand AL, Menezes RJ, Moysich KB. Association of regular aspirin use and breast cancer risk. Oncology 2005; 68: 40-47.
62. Egan KM, Stampfer MJ, Giovannucci E et al. Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 1996; 88: 988-993.
63. Cotterchio M, Kreiger N, Sloan M, Steingart A. Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10: 1213-1217.
64. Johnson TW, Anderson KE, Lazovich D, Folsom AR. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev 2002; 11: 1586-1591.
65. Marshall SF, Bernstein L, Anton-Culver H et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 2005; 97: 805-812.
66. Gierach GL, Lacey JV Jr, Schatzkin A et al. Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res 2008; 10: R38.
67. Eliassen AH, Chen WY, Spiegelman D et al. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses' Health Study II. Arch Intern Med 2009; 169: 115-121; discussion 121.
68. Bardia A, Olson JE, Vachon CM et al. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat 2011; 126: 149-155.
69. Garcia Rodriguez LA, Gonzalez-Perez A. Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer 2004; 91: 525-529.
70. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006; 6: 27.
71. Ready A, Velicer CM, McTiernan A, White E. NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat 2008; 109: 533-543.
72. Brasky TM, Bonner MR, Moysich KB et al. Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control 2010; 21: 1503-1512.
73. Harris RE, Chlebowski RT, Jackson RD et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003; 63: 6096-6101.
74. Zhang Y, Coogan PF, Palmer JR et al. Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the Case-Control Surveillance Study revisited. Am J Epidemiol 2005; 162: 165-170.
75. Gill JK, Maskarinec G, Wilkens LR et al. Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol 2007; 166: 1150-1158.
76. Bosco JL, Palmer JR, Boggs DA et al. Regular aspirin use and breast cancer risk in US Black Women. Cancer Causes Control 2011; 22: 1553-1561.
77. Kirsh VA, Kreiger N, Cotterchio M et al. Nonsteroidal antiinflammatory drug use and breast cancer risk: subgroup findings. Am J Epidemiol 2007; 166: 709-716.
78. Brasky TM, Bonner MR, Moysich KB et al. Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype. Cancer Causes Control 2011; 22: 965-975.
79. Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998; 77: 511-515.
80. Perron L, Bairati I, Moore L, Meyer F. Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 2003; 106: 409-415.
81. Garcia Rodriguez LA, Gonzalez-Perez A. Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 649-653.
82. Harris RE, Beebe-Donk J, Alshafie GA. Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade. Chapter 9. In Harris RE (ed), Inflammation in the Pathogenesis of Chronic Diseases. New York: Springer 2007; 193-212.
83. Salinas CA, Kwon EM, FitzGerald LM et al. Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol 2010; 172: 578-590.
84. Brasky TM, Velicer CM, Kristal AR et al. Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Epidemiol Biomarkers Prev 2010; 19: 3185-3188.
85. Menezes RJ, Swede H, Mettlin C, Moysich KB. Regular aspirin use and risk of prostate cancer. In Proceedings of the American Association for Cancer Research Annual Meeting 43:933. San Francisco, CA 2002.
86. Menezes RJ, Swede H, Niles R, Moysich KB. Regular use of aspirin and prostate cancer risk (United States). Cancer Causes Control 2006; 17: 251-256.
87. Habel LA, Zhao W, Stanford JL. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 2002; 13: 427-434.
88. Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL. Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006. Int J Cancer 2011; 128: 2444-2452.
89. Platz EA, Rohrmann S, Pearson JD et al. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 2005; 14: 390-396.
90. Bosetti C, Talamini R, Negri E et al. Aspirin and the risk of prostate cancer. Eur J Cancer Prev 2006; 15: 43-45.
91. Mahmud SM, Franco EL, Turner D et al. Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS One 2011; 6: e16412.
92. Jacobs EJ, Rodriguez C, Mondul AM et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005; 97: 975-980.
93. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006; 119: 624-638.
94. Huang ES, Strate LL, Ho WW et al. A prospective study of aspirin use and the risk of gastrointestinal bleeding in men. PLoS One 2010; 5: e15721.
95. Sandler RS, Halabi S, Baron JA et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883-890.
96. Baron JA, Cole BF, Sandler RS et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-899.
97. Benamouzig R, Deyra J, Martin A et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003; 125: 328-336.
98. Logan RF, Grainge MJ, Shepherd VC et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008; 134: 29-38.
99. Cole BF, Logan RF, Halabi S et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009; 101: 256-266.
100. Burn J, Gerdes AM, Macrae F et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2012; 378: 2081-2087.
101. Sturmer T, Glynn RJ, Lee IM et al. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 1998; 128: 713-720.
102. Cook NR, Lee IM, Gaziano JM et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294: 47-55.
103. Capurso G, Schunemann HJ, Terrenato I et al. Meta-analysis: the use of nonsteroidal anti-inflammatory drugs and pancreatic cancer risk for different exposure categories. Aliment Pharmacol Ther 2007; 26: 1089-1099.
104. McCredie M, Stewart JH, Ford JM, MacLennan RA. Phenacetin-containing analgesics and cancer of the bladder or renal pelvis in women. Br J Urol 1983; 55: 220-224.
105. Piper JM, Tonascia J, Matanoski GM. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med 1985; 313: 292-295.
106. Castelao JE, Yuan JM, Gago-Dominguez M et al. Non-steroidal antiinflammatory drugs and bladder cancer prevention. Br J Cancer 2000; 82: 1364-1369.
107. Fortuny J, Kogevinas M, Garcia-Closas M et al. Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. Cancer Epidemiol Biomarkers Prev 2006; 15: 1696-1702.
108. Fortuny J, Kogevinas M, Zens MS et al. Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study. BMC Urol 2007; 7: 13.
109. Gago-Dominguez M, Yuan JM, Castelao JE et al. Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer 1999; 81: 542-548.
110. Tavani A, La Vecchia C. Epidemiology of renal-cell carcinoma. J Nephrol 1997; 10: 93-106.
111. McLaughlin JK, Lipworth L, Tarone RE. Epidemiologic aspects of renal cell carcinoma. Semin Oncol 2006; 33: 527-533.